Reactome | lenvatinib [cytosol]

Schema > ChemicalDrug > Entries

compartment	[Compartment:70101] cytosol
created	[InstanceEdit:2023392] Rothfels, K, 2011-12-07
crossReference	[DatabaseIdentifier:12020745] Mondo:0004992 [DatabaseIdentifier:9628005] ChEBI:85994
dbId	2023393
disease	[Disease:1500689] cancer
displayName	lenvatinib [cytosol]
inDisease	true
literatureReference	[LiteratureReference:2077545] E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
maxDepth	1
memberOf	[DefinedSet:R-ALL-2077403] Tyrosine kinase inhibitors of FGFR2 mutants [cytosol] [DefinedSet:R-ALL-2077416] Tyrosine kinase inhibitors of FGFR3 mutants [cytosol] [DefinedSet:R-ALL-9669722] type II KIT binding TKIs [cytosol]
modified	[InstanceEdit:9671493] Rothfels, Karen, 2019-12-19
name	lenvatinib E7080
referenceEntity	[ReferenceTherapeutic:iuphar.ligand:7426] lenvatinib [Guide to Pharmacology:7426]
schemaClass	ChemicalDrug
stId	R-ALL-2023393
summation	[Summation:2077543] E7080 is a broad-specificity tyrosine kinase inhibitor that ...

(hasMember)